RxDoctor Payments DataLook up a doctor →

Scott Hacking, MD

Interventional Cardiology · Salt Lake City, UTNPI 1992712285

Payments from drug & device makers

$22,100in general payments, 2019–2025

Across 821 payments — averaging $26.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Abbott$3K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$997
  • Johnson & Johnson$967
  • plus $5K from 37 others

What the payments were for

  • Speaking & faculty fees$4,50020%
  • Travel & lodging$2,77313%
  • Food & beverage$14,81467%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,100 in reported general payments places this provider in the 70th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah

Medicare billing

Part B allowed, 2024
$415,574
Medicare patients
1,615
Services billed
4,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban478$528,519
XareltoRivaroxaban158$189,880
EntrestoSacubitril/Valsartan164$185,317
Repatha SureclickEvolocumab109$74,785
FarxigaDapagliflozin Propanediol51$51,606
MultaqDronedarone Hcl17$31,703
BrilintaTicagrelor55$27,142
JardianceEmpagliflozin15$17,070
Midodrine Hcl118$7,224
Atorvastatin Calcium741$7,111
Potassium Chloride366$6,557
Ranolazine ErRanolazine63$6,481
Praluent PenAlirocumab11$5,587
ClopidogrelClopidogrel Bisulfate468$5,311
Losartan Potassium543$4,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$997$528,519478 claims
Johnson & JohnsonXarelto$967$189,880158 claims
NovartisEntresto$1,190$185,317164 claims
AstraZenecaFarxiga, Brilinta$132$78,748106 claims
Sanofi-aventis U.S. LLCMultaq$49$31,70317 claims
Boehringer IngelheimJardiance$559$17,07015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 45 interventional cardiology providers in Utah.

Other interventional cardiology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →